| Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists A Gillis, AB Gondin, A Kliewer, J Sanchez, HD Lim, C Alamein, ... Science signaling 13 (625), eaaz3140, 2020 | 244 | 2020 |
| Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal! NL Grimsey, CE Goodfellow, EL Scotter, MJ Dowie, M Glass, ES Graham Journal of neuroscience methods 171 (1), 78-86, 2008 | 146 | 2008 |
| Real‐time characterization of cannabinoid receptor 1 (CB1) allosteric modulators reveals novel mechanism of action EE Cawston, WJ Redmond, CM Breen, NL Grimsey, M Connor, M Glass British Journal of Pharmacology 170 (4), 893-907, 2013 | 113 | 2013 |
| Cannabinoid receptor 2 undergoes Rab5-mediated internalization and recycles via a Rab11-dependent pathway NL Grimsey, CE Goodfellow, M Dragunow, M Glass Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1813 (8), 1554-1560, 2011 | 89 | 2011 |
| Gαs signalling of the CB1 receptor and the influence of receptor number DB Finlay, EE Cawston, NL Grimsey, MR Hunter, A Korde, VK Vemuri, ... British Journal of Pharmacology 174 (15), 2545-2562, 2017 | 84 | 2017 |
| Cannabinoid receptor 1 trafficking and the role of the intracellular pool: implications for therapeutics NL Grimsey, ES Graham, M Dragunow, M Glass Biochemical pharmacology 80 (7), 1050-1062, 2010 | 79 | 2010 |
| GPR18 undergoes a high degree of constitutive trafficking but is unresponsive to N-Arachidonoyl Glycine DB Finlay, WR Joseph, NL Grimsey*, M Glass* PeerJ 4, e1835, 2016 | 77 | 2016 |
| Cannabinoid CB1 and CB2 receptor-mediated arrestin translocation: species, subtype, and agonist-dependence MS Ibsen, DB Finlay, M Patel, JA Javitch, M Glass, NL Grimsey Frontiers in pharmacology 10, 350, 2019 | 71 | 2019 |
| Cannabinoid Receptor 2 (CB2) Signals via G-alpha-s and Induces IL-6 and IL-10 Cytokine Secretion in Human Primary Leukocytes Y Saroz, DT Kho, M Glass, ES Graham, NL Grimsey ACS Pharmacology and Translational Science, https://doi.org/10.1021/acsptsci …, 2019 | 66 | 2019 |
| Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists M Patel, JJ Manning, DB Finlay, JA Javitch, SD Banister, NL Grimsey, ... Biochemical Pharmacology 175, 113871, 2020 | 46 | 2020 |
| Cannabinoid receptor CB2 is expressed on vascular cells, but not astroglial cells in the post-mortem human Huntington's disease brain MJ Dowie, NL Grimsey, T Hoffman, RLM Faull, M Glass Journal of Chemical Neuroanatomy, 2014 | 41 | 2014 |
| A novel high‐throughput assay for the quantitative assessment of receptor trafficking NL Grimsey, PJ Narayan, M Dragunow, M Glass Clinical and Experimental Pharmacology and Physiology 35 (11), 1377-1382, 2008 | 36 | 2008 |
| Development of High-Specificity Fluorescent Probes to Enable Cannabinoid Type 2 Receptor Studies in Living Cells R Sarott, M Westphal, P Pfaff, C Korn, D Sykes, G Thais, B Brennecke, ... Journal of the American Chemical Society 142, 16953-64, 2020 | 34 | 2020 |
| Chromenopyrazole-based high affinity, selective fluorescent ligands for cannabinoid type 2 receptor S Singh, CRM Oyagawa, C Macdonald, NL Grimsey, M Glass, AJ Vernall ACS Medicinal Chemistry Letters 10 (2), 209-214, 2019 | 33 | 2019 |
| Identification of N‐arachidonoyl dopamine as a highly biased ligand at cannabinoid CB1 receptors WJ Redmond, EE Cawston, NL Grimsey, J Stuart, AR Edington, M Glass, ... British Journal of Pharmacology 173 (1), 115-127, 2016 | 28 | 2016 |
| Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines CRM Oyagawa, SM de la Harpe, Y Saroz, M Glass, AJ Vernall, ... Frontiers in Pharmacology 9, 1202, 2018 | 27 | 2018 |
| Developing the Cannabinoid Receptor 2 (CB2) pharmacopoeia: past, present, and future ZM Whiting, J Yin, SM de la Harpe, AJ Vernall, NL Grimsey Trends in Pharmacological Sciences 43 (9), 754-771, 2022 | 26 | 2022 |
| Blood-spinal cord barrier leakage is independent of motor neuron pathology in ALS S Waters, M Swanson, B Dieriks, Y Zhang, N Grimsey, H Murray, C Turner, ... Acta Neuropathologica Communications 9 (https://doi.org/10.1186/s40478-021 …, 2021 | 26 | 2021 |
| Development of selective, fluorescent cannabinoid type 2 receptor ligands based on a 1, 8-naphthyridin-2-(1 H)-one-3-carboxamide scaffold AG Cooper, CRM Oyagawa, JJ Manning, S Singh, S Hook, NL Grimsey, ... Medchemcomm 9 (12), 2055-2067, 2018 | 21 | 2018 |
| Real-time measurement of cannabinoid receptor-mediated cAMP signaling MR Hunter, DB Finlay, CE Macdonald, EE Cawston, NL Grimsey, M Glass Methods in enzymology 593, 43-59, 2017 | 17 | 2017 |
Michelle GlassUniversity of OtagoVerified email at otago.ac.nz
